Individualized Treatment Rules Based on Cost-Effectiveness Criteria in Microsimulations [0.03%]
基于成本效益标准的个体化治疗方案模拟研究
Niklaus Meier,Ana Cecilia Quiroga Gutierrez,Mark Pletscher et al.
Niklaus Meier et al.
Background and objective: In cost-effectiveness analysis, treatment decisions are analysed at the population level. Combinations of treatment strategies that account for the heterogeneity of costs and effects across patie...
Improving Collaborative Engagement in Health State Valuation: A Scoping Review of Current Practices and Emerging Recommendations [0.03%]
改善健康状态估值中的协作参与：当前实践和新兴建议的综述性回顾
Philip A Powell,Victoria Gale,Gurdas Singh et al.
Philip A Powell et al.
Background and objective: Collaborative engagement with individuals invested in or affected by health research, beyond researchers themselves, is advantageous and encouraged by major funding bodies. However, the degree of...
External Validation of the MicroSimulation Core Obesity Model (MS-COM) to Predict Cardiovascular Outcomes, Mortality and Type 2 Diabetes Mellitus Incidence and Assess Cost Effectiveness [0.03%]
MS-COM预测心血管结局、死亡率和2型糖尿病发病率并评估成本效益的外部验证
Christopher G Fawsitt,Howard Thom,David Aceituno et al.
Christopher G Fawsitt et al.
Background and objective: The reliability of a decision model to guide decision making depends on its ability to accurately predict patient outcomes. We present results of an external validation of the MicroSimulation Cor...
Cost Effectiveness of Efanesoctocog Alfa Versus Factor VIII Extended Half-Life in Adolescent and Adult Patients with Hemophilia A in the USA [0.03%]
在美国血友病A患者中艾尼妥莫珠单抗与长效凝血八因子的经济性分析：青少年及成人
Amy Dymond,Alix Arnaud,Ion Agirrezabal et al.
Amy Dymond et al.
Background and objective: Efanesoctocog alfa is a first-in-class high-sustained factor VIII therapy approved for prophylaxis, on-demand treatment, and peri-operative management of bleeding in hemophilia A. This analysis a...
Re-anchoring the Value of Innovative Therapies in NICE Decision Making When Comparators are Cost Ineffective: A Case Study of Late-Onset Pompe Disease [0.03%]
comparator成本效益不佳时NICE决策中重新确定创新疗法价值的锚点——以晚发型庞培病为例
Matthew Walton,Nyanar J Deng,Mark Corbett et al.
Matthew Walton et al.
National Institute for Health and Care Excellence (NICE) technology appraisal processes assume that the standard of care (SoC) is itself cost effective. However, many treatments in use in the UK National Health Service (NHS), particularly i...
Mapping Health State Utility from Disease-Specific Measures in Spinal Muscular Atrophy and Paroxysmal Nocturnal Hemoglobinuria [0.03%]
脊髓性肌肉萎缩症和阵发性夜间血红蛋白尿症的疾病特异性测量方法在绘制健康状况效用中的应用
Ziwen Zhao,Zhao Shi,Lei Dou et al.
Ziwen Zhao et al.
Background: An economic evaluation is widely used to facilitate decision making regarding drug reimbursement in many healthcare systems. However, the absence of preference-based measurement in clinical trials has hindered...
Caring for and Caring about in Economic Evaluation: Modelling the Family and Caregiving Effects [0.03%]
关怀与关爱在经济评估中的作用：家庭和护理影响的建模分析
Becky Pennington,Sarah Davis,Holly Cranmer
Becky Pennington
Current methods for modelling spillover effects on carers in economic evaluation include four main methods: (absolute) utilities, disutilities, increments and multipliers. Each of these approaches assumes that the spillover effect is one-di...
Comment on "Cost Comparisons in NICE Technology Appraisals: An External Assessment Group Perspective" by Marten J. Poley et al [0.03%]
关于Marten J. Poley等人发表的“从外部评估小组视角看NICE技术评估中的成本比较”之评论
Alexander Allen,Alan Lovell,Ahmed Abdelsabour et al.
Alexander Allen et al.
Isaac Corro Ramos
Isaac Corro Ramos
Reply to Comment on "Cost Comparisons in NICE Technology Appraisals: An External Assessment Group Perspective" [0.03%]
对《英国国家卫生与临床优化研究所技术评估中的成本比较：外部评估小组的视角》一文的回信
Marten J Poley,Nigel Armstrong,Huiqin Yang et al.
Marten J Poley et al.